Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL2056 Target Snapshot

D(1A) dopamine receptor · SINGLE PROTEIN · Homo sapiens

5,483Compounds
839Assays
127Approved Drugs
4,706.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-13

D(1A) dopamine receptor shows approved-linked disease relevance led by hemorrhage. 5 more disease programs remain visible in the same review block. 1 linked drug keeps the current disease frame grounded. Protein identity stays anchored to UniProt P21728. Start with hemorrhage, then reuse UniProt P21728 as the stable protein anchor across project notes and exports.

Review focus
Review-ready target frame

Start with hemorrhage, then reuse UniProt P21728 as the stable protein anchor across project notes and exports.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-13 1 linked drug
Open source guide
Disease program
hemorrhage

D(1A) dopamine receptor shows approved-linked disease relevance led by hemorrhage. 5 more disease programs remain visible in the same review block. 1 linked drug remains visible in the same block.

Start review with hemorrhage because it currently carries approved-linked support. Linked drugs include METHYLERGONOVINE MALEATE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Disease source · ChEMBL drug mechanism + indication proxy
Approved-linked Open Targets-ready proxy 1 linked drug
Open disease block
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats D(1A) dopamine receptor as ChEMBL target CHEMBL2056, mapped to UniProt P21728. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
D(1A) dopamine receptor
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL2056
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P21728
D(1A) dopamine receptor
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether D(1A) dopamine receptor is the right protein anchor across sources, using UniProt P21728 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need to confirm why hemorrhage is currently framed as approved-linked support. It currently carries 1 linked drug in the same disease frame.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelD(1A) dopamine receptor
UniProt AccessionP21728
Component TypeProtein
Sequence Length446 aa

D(1A) dopamine receptor

Source · UniProt accession via ChEMBL component mapping
Review Cue

How to read this target

Review this target as D(1A) dopamine receptor, mapped to UniProt P21728. Sequence length is 446 aa.

Mapped IDP21728
Review nameD(1A) dopamine receptor
OrganismHomo sapiens
Disease Relevance

Disease Relevance & Evidence Level

Open Targets-ready disease context using the current target-indication evidence contract.

Approved-linked Open Targets-ready proxy

D(1A) dopamine receptor shows approved-linked disease relevance led by hemorrhage. 5 more disease programs remain visible in the same review block.

Approved-linked Approved
hemorrhage
1 linked drug · 1 direct · 1 efficacy
Linked drugMETHYLERGONOVINE MALEATE
Approved-linked Approved
hypertension
1 linked drug · 1 direct · 1 efficacy
Linked drugFENOLDOPAM MESYLATE
Late clinical Phase III
Parkinson disease
2 linked drugs · 2 direct · 2 efficacy
Linked drugMEVIDALEN
Linked drugTAVAPADON
Late clinical Phase III
Tourette syndrome
1 linked drug · 1 direct · 1 efficacy
Linked drugECOPIPAM
Clinical signal Phase II
Acute kidney injury
1 linked drug · 1 direct · 1 efficacy
Linked drugFENOLDOPAM MESYLATE
Clinical signal Phase II
gambling behaviour
1 linked drug · 1 direct · 1 efficacy
Linked drugECOPIPAM
Source · ChEMBL drug mechanism + indication proxy
Review Cue

How to read disease relevance

Start review with hemorrhage because it currently carries approved-linked support. Linked drugs include METHYLERGONOVINE MALEATE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Lead diseasehemorrhage
Strongest levelApproved-linked
Block modeOpen Targets-ready proxy
Clinical Profile

Clinical Phase Distribution

127
Approved
13
Phase III
25
Phase II
1
Phase I
Assay Mix

Activity Type Distribution

IC501,081.0
KI3,016.0
EC50572.0
KD37.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL1814790 10.0 Ki 0.1 Preclinical
CHEMBL62 9.96 Ki 0.11 Preclinical
CHEMBL1196161 9.92 EC50 0.12 Preclinical
CHEMBL3039528 9.89 Ki 0.13 Clinical
CHEMBL434215 9.82 Kd 0.15 Preclinical
CHEMBL1256645 9.77 Ki 0.17 Preclinical
CHEMBL574558 9.7 EC50 0.2 Preclinical
CHEMBL596824 9.7 Ki 0.2 Preclinical
CHEMBL599135 9.7 Ki 0.2 Preclinical
CHEMBL599528 9.7 Ki 0.2 Preclinical
Distribution

pChEMBL Value Distribution

164
5.0
329
5.5
414
6.0
421
6.5
358
7.0
251
7.5
205
8.0
130
8.5
72
9.0
37
9.5
pChEMBL
Approved Drugs

Approved Drugs

LUMATEPERONE TOSYLATE
CHEMBL3233142
Approved 2019
BREXPIPRAZOLE
CHEMBL2105760
Approved 2015
ASENAPINE
CHEMBL3187365
Approved 2009
PALIPERIDONE
CHEMBL1621
Approved 2006
ROTIGOTINE
CHEMBL1303
Approved 2006
ARIPIPRAZOLE
CHEMBL1112
Approved 2002
APOMORPHINE
CHEMBL53
Approved 2001
ZIPRASIDONE
CHEMBL708
Approved 2001
KETOTIFEN FUMARATE
CHEMBL1633
Approved 1999
KETOTIFEN
CHEMBL534
Approved 1999
FENOLDOPAM
CHEMBL588
Approved 1997
QUETIAPINE
CHEMBL716
Approved 1997
CABERGOLINE
CHEMBL1201087
Approved 1996
SERTINDOLE
CHEMBL12713
Approved 1996
AZELASTINE HYDROCHLORIDE
CHEMBL1200809
Approved 1996
OLANZAPINE
CHEMBL715
Approved 1996
CARVEDILOL
CHEMBL723
Approved 1995
NEFAZODONE HYDROCHLORIDE
CHEMBL1200492
Approved 1994
RISPERIDONE
CHEMBL85
Approved 1993
EBASTINE
CHEMBL305660
Approved 1990
CLOMIPRAMINE
CHEMBL415
Approved 1989
CLOZAPINE
CHEMBL42
Approved 1989
PERGOLIDE
CHEMBL531
Approved 1988
PIMOZIDE
CHEMBL1423
Approved 1984
HALOPROGIN
CHEMBL1289
Approved 1982
AMOXAPINE
CHEMBL1113
Approved 1980
MAPROTILINE
CHEMBL21731
Approved 1980
CLEMASTINE
CHEMBL1626
Approved 1977
DOPAMINE
CHEMBL59
Approved 1974
DOPAMINE HYDROCHLORIDE
CHEMBL1557
Approved 1974
DROPERIDOL
CHEMBL1108
Approved 1970
DOXEPIN
CHEMBL1628227
Approved 1969
HALOPERIDOL
CHEMBL54
Approved 1967
CHLORPROTHIXENE
CHEMBL908
Approved 1967
NORTRIPTYLINE
CHEMBL445
Approved 1964
THIORIDAZINE
CHEMBL479
Approved 1962
METHYSERGIDE
CHEMBL1065
Approved 1962
AMITRIPTYLINE
CHEMBL629
Approved 1961
CYPROHEPTADINE
CHEMBL516
Approved 1961
FLUPHENAZINE
CHEMBL726
Approved 1959
CHLORPROMAZINE
CHEMBL71
Approved 1957
PROCHLORPERAZINE
CHEMBL728
Approved 1956
ERGOTAMINE
CHEMBL442
Approved 1948
METHYLERGONOVINE
CHEMBL1201356
Approved 1946
Assay Landscape

Assay Landscape

841
Total Assays
1,451
Tested Compounds
4
Assay Types
Binding — 657 assays, 1,451 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 449 475 6.9
cell-based format 168 661 6.8
cell membrane format 17 97 6.0
assay format 15 198 7.2
organism-based format 5 0
tissue-based format 3 20 6.6
Functional — 171 assays, 323 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 128 251 7.0
assay format 36 31 7.3
single protein format 3 3 6.7
tissue-based format 3 37 7.4
cell membrane format 1 1 4.8
ADME — 12 assays, 1 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 8 1 7.9
single protein format 4 0
Unassigned — 1 assays, 0 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 1 0

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine